Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RegoNivo vs Standard of Care Chemotherapy in AGOC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
- Status
- UNKNOWN
- Phase
- PHASE2
Pre-operative Immunotherapy in Stage II-III Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
- Status
- UNKNOWN
- Phase
- NA
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
- Status
- COMPLETED
- Phase
- PHASE2
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2